To improve the actions available to eligible product developers in the event of delays in receiving covered product for purposes of generic drug or biosimilar biological product development.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill provides amendments to actions for delays of generic drugs and biosimilar biological products Section 610 of division N of the Further Consolidated Appropriations Act, 2020 (Public Law 116–94; 21 U.S.C. It relies on definition changes, appropriations, compliance mandates, and product standards. The main policy areas are Healthcare Consumers, Finance, Housing, and Healthcare.
Who Benefits and How
Patients and health care consumers affected by the bill could gain revenue opportunities, Homeowners, tenants, or housing market participants affected by the bill could gain revenue opportunities, and Businesses and employers affected by the bill could gain revenue opportunities.
Who Bears the Burden and How
Federal, state, or local agencies responsible for implementing the clause would take on compliance duties.
Key Provisions
- Provides amendments to actions for delays of generic drugs and biosimilar biological products Section 610 of division N of the Further Consolidated Appropriations Act, 2020 (Public Law 116–94; 21 U.S.C.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill provides amendments to actions for delays of generic drugs and biosimilar biological products Section 610 of division N of the Further Consolidated Appropriations Act, 2020 (Public Law 116–94; 21 U.S.C.
Key Policy Areas
Healthcare Consumers, Finance, Housing, Healthcare
Primary Purpose
The bill provides amendments to actions for delays of generic drugs and biosimilar biological products Section 610 of division N of the Further Consolidated Appropriations Act, 2020 (Public Law 116–94; 21 U.S.C.
Policy Domains
Whole bill
Identified Gains
- Patients and health care consumers affected by the bill
- Homeowners, tenants, or housing market participants affected by the bill
- Businesses and employers affected by the bill
Identified Costs
- Federal, state, or local agencies responsible for implementing the clause
Sponsors
Legislative Progress
IntroducedMs. Hassan (for herself and Mr. Braun) introduced the following …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology